Viewport 03 · Claim Ownership
Who owns the language consumers reach for
Eighteen brands on the vertical. Ten claim categories on the horizontal. Cell intensity shows how strongly each brand owns the claim. AXIV's strongest column is compare-to. AXIV's only structurally distinct claim is quantified onset, and it sits at SKU level only.
0 = absent · 3 = category-defining
What incumbents own
And what AXIV does not
- Vicks · Day/Night occasion, #1 Pharmacist Recommended, 125 years
- Mucinex · Mucus authority, "1200 mg of Guaifenesin", 12-hour
- Tylenol · #1 Doctor recommended pain reliever (parent transfer)
- Zicam · Duration-modification, "shorten a cold at first sign"
- Theraflu · Phenylephrine-free first-mover, "Right to Rest and Recover"
- Sambucol · Original Black Elderberry, daily-use claim
- Zarbee's · #1 pediatrician-recommended for kids 12 and under
- Genexa · Clean Medicine, same actives clean label
What no one owns
White-space claim territory
- Adult clean-medicine specialist. Genexa skews family. Zarbee's skews kids. The adult clean-OTC shopper has no anchor brand.
- Symptom-specific natural cold and flu. Mucinex has no clean frame. The elderberry buyer has no clean answer for congestion.
- Bilingual, Latin-pharma-anchored natural-immune. Boiron has one Spanish page. No brand owns the heritage.
- Daytime relief without phenylephrine. Theraflu owns it in hot-drink format only. No softgel brand has claimed it as a master frame.
- Sick-day permission as master frame. Zicam owns it in fragments. Vicks owns it implicitly via DayQuil.
What AXIV uniquely owns today
And why it is buried
- "Works in as little as 30 minutes" (Sinus Severe). The only numeric onset claim on the homepage of any mainstream OTC. Currently buried at SKU detail level.
- "VroZzz help you fall asleep in as little as 20 minutes". Olly, Vitafusion, Goli sleep gummies publish no minute-level claims.
- Branded compare-to posture. Every chain private label uses this rhetoric. No other branded competitor in the formal scan does. Whether asset or exposure is the strategy question.
- Note. Master-brand language ("Relief in every dose") does not pick up either onset claim. The distinctive claim territory exists at SKU level only.
What the heat map shows
Claim density is concentrated. AXIV is concentrated in the wrong column.
The matrix has four dense columns and six sparse ones. Mechanism, Trust and Heritage, Severity, and Daily Immune carry most of the category's claim weight. Speed, Won't Knock Out, Safe for Kids, Clean, Compare-to, and Nighttime carry less. AXIV's row shows weight in Speed (the Sinus 30-minute onset), Nighttime (VroZzz, GemSleep), Won't Knock Out (the "does not cause drowsiness" line on DayTime), and Compare-to (the Vicks, NyQuil, Benadryl, Sinex references). Every other column is empty or near-empty.
Compare-to is the column where AXIV reads most strongly, and that column has one other entry across the eighteen brands. The "compare to" rhetorical convention sits with private label (Equate, Up & Up, Amazon Basic Care, CVS Health) outside the formal scan. Inside the scan only AXIV uses it. The shopper who values that rhetoric typically buys retailer private label, not a branded entrant making private-label noises. A category buyer at CVS or Walgreens reads the AXIV row as a misfit. It sits adjacent to their own private label and does not anchor to a positioning territory the chain would want to bring to shelf.
Two claim territories AXIV could surface are the quantified onset claims, today buried at SKU detail level. "Works in as little as 30 minutes" and "fall asleep in as little as 20 minutes" are dose-anchored numeric claims that no mainstream OTC publishes at the homepage surface. Surfacing them at master-brand level requires either dropping the compare-to row entirely or making onset specificity the new compare-to substitute. Whichever territory the rebrand selects, the existing compare-to slot does not stack into the next rank tier. It stacks AXIV alongside Equate.